BioNTech Buys CureVac in $1.25 Billion mRNA Cancer Bet
BioNTech has agreed to acquire German biotech rival CureVac in a $1.25 billion all-stock deal, strengthening its ambitions in mRNA-based...
BioNTech has agreed to acquire German biotech rival CureVac in a $1.25 billion all-stock deal, strengthening its ambitions in mRNA-based...
The U.S. Treasury yield is expected to decrease in the coming months as investors predict the Federal Reserve will cut...
Ptsident Trump announced on Wednesday that the U.S.-China trade agreement is finalized but many details remain unclear. Through his Truth...
uThe $24.7 billion withdrawal from U.S. stock funds by global investors during May occurud because they moved their money to...
The World Bank reduced its 2025 global economic growth projection because rising tariffs together with increasing economic uncertainty create major...